<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03433534</url>
  </required_header>
  <id_info>
    <org_study_id>RIPH3-RNI17/NIVEAL</org_study_id>
    <secondary_id>2017-A02788-45</secondary_id>
    <secondary_id>2017.12.08</secondary_id>
    <nct_id>NCT03433534</nct_id>
  </id_info>
  <brief_title>Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer</brief_title>
  <acronym>NIVEAL</acronym>
  <official_title>Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the relationship between progression free survival of patients treated with
      nivolumab for metastatic non small cell lung carcinoma or a metastatic renal cell carcinoma
      and nivolumab blood concentration.

      Collection of standard data prospectively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nivolumab is a monoclonal antibody used for the treatment of non small cell lung carcinoma
      and renal cell carcinoma. Huge variability exists between patients treated by nivolumab in
      terms of efficacy and side effects. Like others monoclonal antibodies, a relation between
      concentration and effects of nivolumab may exist.

      The aim of this study is to assess the relationship between blood concentration of nivolumab
      and progression free survival, overall survival and side effects on the one hand, and on the
      other to describe pharmacokinetic of nivolumab
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to one year</time_frame>
    <description>Association between nivolumab concentration and progression free survival : time from start of nivolumab treatment to progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to one year</time_frame>
    <description>Association between nivolumab concentration and overall survival : time from start of nivolumab treatment to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target concentration</measure>
    <time_frame>14 days</time_frame>
    <description>Determination of nivolumab concentration associated with clinical benefit (complete response + partial response + stable disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>14 days</time_frame>
    <description>Association between nivolumab residual concentration and side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nivolumab PK parameters : distribution volume</measure>
    <time_frame>Baseline up to one year</time_frame>
    <description>Nivolumab residual concentrations will be measured each 14 days until the end of the study (up to one year).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nivolumab PK parameters : clearance</measure>
    <time_frame>Baseline up to one year</time_frame>
    <description>Nivolumab residual concentrations will be measured each 14 days until the end of the study (up to one year).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Kidney Cancer</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Pharmacokinetic of Nivolumab</arm_group_label>
    <description>Patients under nivolumab (Opdivo 10 MG/ML) for the treatment of non small cell lung carcinoma or renal cell carcinoma. Measure of nivolumab residual concentration 14 days after administration of nivolumab and just before the new perfusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacokinetic of Nivolumab</intervention_name>
    <description>Nivolumab residual concentration is measured 14 days after administration of nivolumab 3 mg/kg as an intravenous infusion just before the new administration.</description>
    <arm_group_label>Pharmacokinetic of Nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be drawn to all patients to measure nivolumab concentration
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with nivolumab at CHRU of Tours for squamous or non squamous non small
        cell lung cancer stage IV or renal cell carcinoma stage IV
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with squamous or non squamous non small cell lung cancer stage IV or patient
             with renal cell carcinoma stage IV

          -  Patient receiving nivolumab or who will receive nivolumab

          -  Age ⩾ 18 years old

          -  OMS stage ≤ 2

          -  Evaluable disease

        Exclusion Criteria:

          -  Active brain metastasis not treated before by surgery or radiotherapy

          -  Autoimmune disease

          -  Patient having objected to the processing of his data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claude Linassier</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hélène Salaun</last_name>
    <phone>02 47 47 99 19</phone>
    <phone_ext>+33</phone_ext>
    <email>salaunhelene@hotmail.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claude Linassier</last_name>
    <phone>02 47 47 99 19</phone>
    <phone_ext>+33</phone_ext>
    <email>claude.linassier@univ-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical oncology department, University Hospital, Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène SALAUN</last_name>
      <email>salaunhelene@hotmail.fr</email>
    </contact>
    <investigator>
      <last_name>Claude LINASSIER, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pneumology department, University Hospital, Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helene SALAUN</last_name>
      <email>salaunhelene@hotmail.fr</email>
    </contact>
    <investigator>
      <last_name>Eric PICHON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2018</study_first_submitted>
  <study_first_submitted_qc>February 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nivolumab</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>Opdivo</keyword>
  <keyword>antineoplastic agent</keyword>
  <keyword>ELISA</keyword>
  <keyword>pharmacokinetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

